Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016;388:488–497.

• Crossref
• PubMed
Tap WD, Jones RL, Van Tine BA, Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016;388:488–497.10.1016/S0140-6736(16)30587-627291997)| false
• Search Google Scholar
• Export Citation

Phase III ANNOUNCE trial. Available at: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-results-phase-3-soft-tissue-sarcoma-study. Accessed May 16, 2019.

• PubMed
Phase III ANNOUNCE trial. Available at: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-results-phase-3-soft-tissue-sarcoma-study. Accessed May 16, 2019.)| false
• Export Citation

US Food & Drug Administration. Olaratumab (LARTRUVO). FDA statement January 24, 2019. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm. Updated January 25, 2019. Accessed April 18, 2019.

• PubMed
US Food & Drug Administration. Olaratumab (LARTRUVO). FDA statement January 24, 2019. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm. Updated January 25, 2019. Accessed April 18, 2019.)| false
• Search Google Scholar
• Export Citation

van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–1886.

• Crossref
• PubMed
van der Graaf WT, Blay JY, Chawla SP, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–1886.10.1016/S0140-6736(12)60651-5)| false
• Search Google Scholar
• Export Citation

Mir O, Cropet C, Toulmonde M, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016;17:632–641.

• Crossref
• PubMed
Mir O, Cropet C, Toulmonde M, Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016;17:632–641.10.1016/S1470-2045(16)00075-927068858)| false
• Search Google Scholar
• Export Citation

Stacchiotti S, Mir O, Le Cesne A, et al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist 2018;23:62–70.

• Crossref
• PubMed
Stacchiotti S, Mir O, Le Cesne A, Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist 2018;23:62–70.2875472110.1634/theoncologist.2017-0161)| false
• Search Google Scholar
• Export Citation

Groisberg R, Hong DS, Behrang A et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 2017;5:100.

• Crossref
• PubMed
Groisberg R, Hong DS, Behrang A Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 2017;5:100.10.1186/s40425-017-0301-y29254498)| false
• Search Google Scholar
• Export Citation

Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 2018;379:2417–2428.

• Crossref
• PubMed
Gounder MM, Mahoney MR, Van Tine BA, Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 2018;379:2417–2428.10.1056/NEJMoa180505230575484)| false
• Search Google Scholar
• Export Citation

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

• Crossref
• PubMed
Drilon A, Laetsch TW, Kummar S, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.2946615610.1056/NEJMoa1714448)| false
• Search Google Scholar
• Export Citation

Heinrich M, von Mehren M, Jones RL, et al. Avapritinib is highly active and well-tolerated in patients (pts) with advanced GIST driven by diverse variety of oncogenic mutations in KIT and PDGFRA [abstract]. Presented at 2018 CTOS Annual Meeting; November 14–17, 2018; Rome, Italy. Paper 012.

• PubMed
Heinrich M, von Mehren M, Jones RL, Avapritinib is highly active and well-tolerated in patients (pts) with advanced GIST driven by diverse variety of oncogenic mutations in KIT and PDGFRA [abstract]. Presented at 2018 CTOS Annual Meeting; November 14–17, 2018; Rome, Italy. Paper 012.)| false
• Export Citation

George S, Heinrich M, Chi P, et al. Initial results of phase 1 study of DCC-2618, a broad-spectrum KIT and PDGFRA inhibitor, in patients (PTS) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Presented at the 2018 CTOS Annual Meeting; November 14–17, 2018; Rome, Italy. Paper 013.

• PubMed
George S, Heinrich M, Chi P, Initial results of phase 1 study of DCC-2618, a broad-spectrum KIT and PDGFRA inhibitor, in patients (PTS) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Presented at the 2018 CTOS Annual Meeting; November 14–17, 2018; Rome, Italy. Paper 013.)| false
• Search Google Scholar
• Export Citation